Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Leerink Partners has raised its price target on Theravance Biopharma (NASDAQ:TBPH) to $13.00 from $10.00 while maintaining a Market Perform rating on the stock. The company’s shares are currently trading near their 52-week high of $11.99, having delivered an impressive year-to-date return of nearly 27%.
The price target increase follows Theravance’s completion of its Trelegy royalty sale for $225 million, receipt of a $7.5 million Yupelri China approval milestone payment, and second-quarter 2025 results that exceeded expectations. InvestingPro data shows the company maintains a strong financial position with a healthy current ratio of 4.77, indicating robust liquidity. Get access to 8 more key ProTips and comprehensive analysis with InvestingPro.
Theravance Biopharma is projected to end 2025 with approximately $320 million in cash and generate an additional $175 million in milestone payments over the next 24 months, according to Leerink Partners.
The company maintained its full-year operating expense guidance and expects its non-GAAP loss and cash burn to approach breakeven in the second half of 2025, demonstrating improved operating leverage.
For the Phase 3 Cypress study of ampreloxetine, Theravance anticipates completing open-label enrollment by late summer, with topline results expected in the first quarter of 2026.
In other recent news, Theravance Biopharma Inc reported robust financial performance for the second quarter of 2025, exceeding analyst expectations. The company’s earnings per share (EPS) reached $1.08, surpassing the forecasted $0.67, which represents a 61.19% surprise. Revenue figures were also impressive, coming in at $26.2 million against the projected $15.92 million, marking a 64.57% surprise. These results highlight Theravance’s strong performance and have drawn positive attention from investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.